Transcleral delivery of triamcinolone acetonide and ranibizumab to retinal tissues using macroesis

Singh, Rishi P.; Mathews, Michael Ellen; Kaufman, Michael D.; Riga, Alan T.

doi:10.1136/bjo.2009.159541

Cited by 16 publications

(9 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In many cases, existing drugs need to be reformulated to confer an electric charge so that they can be utilized within the system. To resolve these problems, Macroesis™ (Buckeye Pharmaceuticals, Beachwood, OH, U.S.) propose using an alternating current instead of DC [159,160].…”

Section: Iontophoresismentioning

confidence: 99%

Recent Advances in Ocular Drug Delivery Systems

2011

View full text Add to dashboard Cite

Abstract:Transport of drugs applied by traditional dosage forms is restricted to the eye, and therapeutic drug concentrations in the target tissues are not maintained for a long duration since the eyes are protected by a unique anatomy and physiology. For the treatment of the anterior segment of the eye, various droppable products to prolong the retention time on the ocular surface have been introduced in the market. On the other hand, direct intravitreal implants, using biodegradable or non-biodegradable polymer technology, have been widely investigated for the treatment of chronic vitreoretinal diseases. There is urgent need to develop ocular drug delivery systems which provide controlled release for the treatment of chronic diseases, and increase patient's and doctor's convenience to reduce the dosing frequency and invasive treatment. In this article, progress of ocular drug delivery systems under clinical trials and in late experimental stage is reviewed.

show abstract

Section: Iontophoresismentioning

confidence: 99%

Recent Advances in Ocular Drug Delivery Systems

2011

View full text Add to dashboard Cite

show abstract

“…4,56 Animal studies have shown successful administration of triamcinolone acetonide and ranibizumab through fullthickness ocular tissue in rabbits. 57,58 OcuPhor, EyeGate, and Visulex are the few ocular iontophoresis systems, which have been developed recently. 59,60,64 Encapsulated cell technology Encapsulated cell technology, developed by Neurotech Pharmaceuticals, is one of the latest innovations in posterior segment sustained drug delivery systems.…”

Section: Suprachoroidal Drug Delivery Via Itrack Microcathetermentioning

confidence: 99%

Posterior Segment Drug Delivery Devices: Current and Novel Therapies in Development

Bansal

Garg²,

Sharma

et al. 2016

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

Ocular drug delivery by conventional routes of administration does not maintain therapeutic drug concentrations in the target tissues for a long duration because of various anatomical and physiological barriers. Treatment of diseases of the posterior segment of the eye requires novel drug delivery systems that can overcome these barriers for efficacious delivery, provide controlled release for the treatment of chronic diseases, and increase patient's and doctor's convenience to reduce the dosing frequency and associated side effects. Thereby, an increasing number of sustained-release drug delivery devices using different mechanisms have been developed. This article discusses various current and future sustained-release drug delivery systems for the posterior segment disorders.

show abstract

“…Transscleral delivery of triamcinalone and Lucentis has been successfully applied in animal models using electrically facilitated macroesis methodology [124]. Dexamethasone has been shown to suppress the release of various pro-inflammatory and pro-angiogenic cytokines from retinal pericytes [125].…”

Section: What Future Frontiers and Direction Are Available For Mtmentioning

confidence: 99%

Potential Therapeutic Roles for Inhibition of the PI3K/Akt/mTOR Pathway in the Pathophysiology of Diabetic Retinopathy

Jacot

Sherris

2011

Journal of Ophthalmology

View full text Add to dashboard Cite

Novel therapeutics such as inhibitors of PI3K/Akt/mTOR pathway presents a unique opportunity for the management of diabetic retinopathy (DR). Second generation mTOR inhibitors have the prospect to be efficacious in managing various stages of disease progression in DR. During early stages, the mTOR inhibitors suppress HIF-1α, VEGF, leakage, and breakdown of the blood-retinal barrier. These mTOR inhibitors impart a pronounced inhibitory effect on inflammation, an early component with diverse ramifications influencing the progression of DR. These inhibitors suppress IKK and NF-κB along with downstream inflammatory cytokines, chemokines, and adhesion molecules. In proliferative DR, mTOR inhibitors suppress several growth factors that play pivotal roles in the induction of pathological angiogenesis. Lead mTOR inhibitors in clinical trials for ocular indications present an attractive treatment option for chronic use in DR with favorable safety profile and sustained ocular pharmacokinetics following single dose. Thereby, reducing dosing frequency and risk associated with chronic drug administration.

show abstract

Transcleral delivery of triamcinolone acetonide and ranibizumab to retinal tissues using macroesis

Abstract: Successful delivery of ranibizumab and triamcinolone acetonide can be achieved with macroesis in preclinical studies.

Cited by 16 publications

References 2 publications

Recent Advances in Ocular Drug Delivery Systems

Recent Advances in Ocular Drug Delivery Systems

Posterior Segment Drug Delivery Devices: Current and Novel Therapies in Development

Potential Therapeutic Roles for Inhibition of the PI3K/Akt/mTOR Pathway in the Pathophysiology of Diabetic Retinopathy

Contact Info

Product

Resources

About